Core Viewpoint - ADMA Biologics and Grifols are prominent players in the plasma-derived therapies market, each with unique strengths and growth prospects, making stock selection challenging [1][2]. Company Overview ADMA Biologics - ADMA specializes in plasma-derived biologics for treating immune deficiencies and preventing infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [3][6]. - Asceniv, the lead product, is a plasma-derived IVIG that contains polyclonal antibodies to neutralize microbes [4][5]. - The company anticipates significant revenue growth from Asceniv, driven by record demand and plans for a new R&D program, SG-001, which could generate $300-500 million in annual revenues [6]. Grifols - Grifols is a global leader in plasma-derived medicines, developing a wide range of biological therapies targeting various immunological conditions [7][8]. - The company reported sales of €7.2 billion in 2024, reflecting a 10.3% increase, and is recognized as the largest producer of A1PI [9][10]. - Grifols has a diverse portfolio and is positioned for consistent growth due to strong demand and operational execution [11]. Financial Estimates ADMA Biologics - The Zacks Consensus Estimate for ADMA's 2025 sales indicates an 18.61% year-over-year increase, with EPS expected to improve by 36.73% [12]. - Recent estimate revisions show a decline in EPS estimates for 2025 but an increase for 2026 [13]. Grifols - The Zacks Consensus Estimate for Grifols' 2025 sales suggests a 3.78% increase, with EPS expected to rise by 296% [12]. - EPS estimates for both 2025 and 2026 have seen upward revisions in the past 60 days [15]. Price Performance and Valuation - Year-to-date, ADMA shares have increased by 15.9%, outperforming Grifols' 10.6% rise, while the industry has declined by 4.1% [16]. - In terms of valuation, ADMA trades at 25.48X forward earnings, significantly higher than Grifols' 7.19X [16]. Investment Recommendation - ADMA shows steady growth driven by Asceniv demand, while Grifols, with a broader portfolio and better valuation, is considered a more favorable investment choice at present [20][21][22].

Group 1 - The article discusses the author's long position in the shares of GRFS and UNM, indicating a positive outlook on these companies [1] - It emphasizes the importance of conducting due diligence and research before making any investment decisions, particularly for short-term trading and options trading [2] - The article clarifies that past performance is not indicative of future results, and no specific investment recommendations are provided [3]

Core Viewpoint - Grifols (GRFS) is currently positioned as a better value opportunity compared to Neurocrine Biosciences (NBIX) based on various valuation metrics and earnings outlook [1][3]. Valuation Metrics - GRFS has a forward P/E ratio of 7.65, significantly lower than NBIX's forward P/E of 31.35, indicating that GRFS may be undervalued [5]. - The PEG ratio for GRFS is 0.26, while NBIX's PEG ratio is 1.22, suggesting that GRFS has a more favorable earnings growth outlook relative to its price [5]. - GRFS's P/B ratio stands at 0.60, compared to NBIX's P/B of 4.63, further highlighting GRFS's relative undervaluation [6]. Earnings Outlook - GRFS has a Zacks Rank of 2 (Buy), indicating a stronger improvement in its earnings outlook compared to NBIX, which has a Zacks Rank of 3 (Hold) [3][6]. - The overall valuation metrics and solid earnings outlook position GRFS as the superior value option in the current market [6].

Company Overview - Grifols conducted a conference call to review its Business Results for the First Quarter of 2025, featuring key executives including the CEO, CFO, and President of Biopharma [1]. Logistics and Presentation - The conference call is expected to last about an hour, including a Q&A session, and is being recorded for future reference [2]. - Additional materials, including the presentation, are available on the Grifols Investor Relations website [2]. Financial Reporting - All financial statements are prepared in accordance with EU IFRS and other applicable reporting provisions, including alternative performance measures (APMs) [4]. - Grifols management utilizes APMs to assess financial performance, cash flow, and overall business health [4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-35193 Grifols, S.A. Form 20-F x Form 40-F ¨ G r i fo l s, S.A. TABLE OF CONTE N T S S e q u e n t i a l P a g e N u m b e r 1. E a rn i n g s P r e s s R e l e a s e , d a t e d M a y 1 2, 2 0 2 5 2. Q 1 2 0 2 5 E a rn i n g s P r e s e n t a t i o n 3 5 (Translation of r ...

Debt and Financial Exposure - As of December 31, 2024, the company had $3.2 billion and €6.0 billion in senior interest-bearing debt, with 29.0% of this debt at variable interest rates[130] - The company has approximately $3.2 billion of U.S. dollar denominated senior debt, increasing its exposure to currency risk[132] - In 2024, €4.8 billion, or 66.6%, of the company's net revenue of €7.2 billion was denominated in U.S. dollars, exposing it to foreign currency exchange rate fluctuations[131] Operational Risks - The company relies on third parties for the sale, distribution, and delivery of its products, which could materially affect its business if these parties fail to perform[140] - The company’s manufacturing capacity could be significantly impacted by accidents or force majeure events, potentially leading to substantial revenue loss[133] - The company’s reliance on third-party suppliers for key components may impair its manufacturing ability if these suppliers fail to deliver[136] - The company’s revenue could be adversely affected by extreme weather conditions and climate change, which may increase operational risks[133] Regulatory and Compliance Challenges - The company is subject to complex and evolving data privacy regulations, which could lead to increased operational costs and compliance challenges[152] - The California Privacy Rights Act (CPRA) was enacted in November 2020, effective January 1, 2023, expanding consumer control over personal information and increasing compliance obligations for businesses[154] - Noncompliance with GDPR can result in penalties of up to €20 million or 4% of global company revenues[156] - The company faces potential costs related to compliance with various data protection regulations, which could adversely affect its business[157] - The ongoing changes and uncertainties surrounding the Affordable Care Act (ACA) could materially affect the company's operations in the United States[188] - Government pressures on reimbursement rates and pricing in the healthcare industry may adversely impact the company's financial performance[190] - The 340B Program requires the company to extend discounts, and changes to this program could negatively affect financial results[191] - The company must report detailed pricing information to CMS, and inaccuracies in this reporting could lead to fines and sanctions that adversely affect business operations[205] - Non-compliance with the 340B Program under the Public Health Service Act could lead to civil monetary penalties of up to $5,000 for each instance of overcharging covered entities[202] - Regulatory approvals are required for marketing products outside the United States, and delays in obtaining these approvals could hinder market entry and revenue generation[206] - The company is required to disclose payments to healthcare providers under the Physician Payment Sunshine Act, which imposes additional compliance costs[207] - Heightened scrutiny over pharmaceutical pricing in the U.S. could impact the company's ability to negotiate sales contracts and pricing agreements[212] - Proposed legislation targeting drug pricing may impose additional pricing pressures on the company's products, potentially affecting profitability[215] Intellectual Property and Patent Risks - The patent landscape in biotechnology is uncertain, and the company may not secure additional patents or face challenges to existing patents, impacting competitive advantage[163] - The company may be subject to substantial costs from patent litigation, which could affect its ability to compete effectively in the marketplace[175] - There is a risk of unauthorized use of the company's intellectual property, which could harm its reputation and commercial interests[169] - The company relies on trade secrets and nondisclosure agreements to protect proprietary information, but these measures may not be fully effective[170] - The company has in-licensed certain patent rights, and any failure of licensors to enforce their rights could impact the company's competitive position[177] - The company may need to obtain additional licenses or renew existing agreements, which could be uncertain and affect its ability to develop and commercialize products[178] Climate Change and Environmental Risks - Climate change poses risks to the company's operations, including physical risks like water scarcity and flooding, which could increase costs and disrupt the supply chain[182] - New regulatory requirements related to climate change may increase operating costs and necessitate additional investments in technology[183] - The company faces risks associated with environmental, health, and safety regulations, which could result in substantial liabilities and compliance costs[219] Market and Shareholder Dynamics - The Grifols Family and Scranton Enterprises B.V. own approximately 36% of Class A shares, exercising 100% voting control[226] - Class B ADSs traded as high as $11.56 on October 1, 2024, and as low as $5.47 on March 13, 2024, closing at $6.52 on April 10, 2025[227] - The company has faced negative publicity from short sellers, which may impact revenues and customer confidence[231] - Fluctuations in the exchange rate between the U.S. dollar and the euro may affect the value of ADSs and shares, increasing volatility[234] - The company may incur significant expenses defending against lawsuits resulting from negative publicity, impacting financial condition[232] - Ineffective internal controls could harm the company's ability to provide reliable financial reports, affecting market confidence[224] - The market price of shares may be influenced by various factors, including short selling and market expectations for financial performance[229] - The company intends to evaluate costs and liabilities associated with registration requirements for any rights offering[239] - The depositary may refuse to transfer ADSs under certain conditions, impacting liquidity for holders[241] Cost Management and Efficiency - A cost savings plan has been implemented to reduce headcount and improve efficiency in plasma procurement, which may lead to unexpected charges and expenses[179] - The company has acquired multiple plasma collection centers, including Canadian Plasma Resources Corporation in 2023 and Haema Plasma Kft. in 2024, as part of its plasma acquisition strategy[179]

Group 1 - The article expresses a beneficial long position in the shares of GRFS, indicating a positive outlook on the company's stock performance [1] - The author emphasizes the importance of conducting due diligence and research prior to any investment, highlighting the risks associated with short-term trading and options trading [2] - It is noted that past performance is not indicative of future results, and no specific investment recommendations are provided [3]

Core Message - Grifols has received a $21 million grant from The Michael J Fox Foundation for Parkinson's Research to identify plasma-based biomarkers for early detection of Parkinson's disease (PD) through the "Chronos-PD" initiative [1][11] - The initiative aims to revolutionize PD management by detecting the disease years before symptoms appear, enabling the development of new diagnostics and disease-modifying therapies [1][4][5] Grifols' Research and Capabilities - Grifols possesses one of the world's largest collections of biospecimens, with over 100 million plasma samples collected over nearly 15 years, representing thousands of disease states [3][5] - The company leverages its proprietary plasma repository, advanced technology platforms, and plasma proteomics expertise to drive innovative research [4][5] - Grifols' subsidiary Alkahest, specializing in AI and multiomics analysis, is leading the Chronos-PD program [12] Parkinson's Disease Context - PD affects nearly 1 million people in the US and over 6 million worldwide, with limited understanding of its drivers despite decades of research [10] - Current PD diagnosis relies on medical history, physical examination, and brain imaging, often detecting the disease too late to significantly slow or reverse its progression [2] Grifols' Broader Impact - Grifols is a global healthcare leader in plasma-derived medicines and transfusion medicine, operating in over 110 countries with more than 23,000 employees [14][16] - The company focuses on treating conditions across various therapeutic areas, including immunology, neurology, and infectious diseases, driven by patient needs and its growing knowledge of chronic and rare conditions [6][7] - Grifols continues to expand its network of donation centers, which is the world's largest with over 390 centers across multiple regions [15]

Core Viewpoint - Grifols has received a $21 million grant from The Michael J. Fox Foundation to develop plasma-based biomarkers for early detection of Parkinson's disease, aiming to enhance diagnostic tools and disease-modifying therapies [1][4][7]. Company Overview - Grifols is a global healthcare company founded in 1909, specializing in plasma-derived medicines and transfusion medicine, with operations in over 110 countries [8][9][10]. - The company has a significant repository of over 100 million plasma samples collected over nearly 15 years, making it one of the largest collections of biospecimens globally [5][8]. Research Initiative - The "Chronos-PD" initiative will analyze longitudinal plasma samples over a period of up to 10 years to track changes in plasma proteins in individuals with Parkinson's disease [4][6]. - The research aims to establish an early-warning system for Parkinson's disease, potentially revolutionizing its management by identifying biomarkers before clinical symptoms appear [7][8]. Technological Approach - Grifols is leveraging advanced technologies, including AI and multiomics analysis, to drive research and development in diagnostic and therapeutic drug discovery [6][8]. - The initiative is expected to not only benefit Parkinson's disease research but also be applicable to other diseases and therapeutic areas [5][6].

Q3 2024 Results - 1 - Q3 2024 Results November 7, 2024 Legal Disclaimer Important Information This presentation does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, the Spanish Securities Market and Inv ...